TABLE 1.
Distribution of GyrA and ParC alteration patterns against respective ofloxacin MICs for sample isolates from Hong Kong in 2001a
| Ofloxacin MIC (μg/ml) | GyrA alteration | ParC alteration (frequency) | Total frequency |
|---|---|---|---|
| <0.1 | Φ | Φ (6) | 6 |
| 0.1-0.5 | Ser-91 → Phe | Φ (7), Glu91 → Ala (1), Glu91 → Gly (1) | 14 |
| Ser91 → Tyr | Φ (4) | ||
| Asp95 → Asn | Φ (1) | ||
| 1 | Ser91 → Tyr | Φ (4) | 14 |
| Ser91 → Phe | Φ (2), Glu91 → Ala (1), Asp86 → Asn (1) | ||
| Ser91 → Phe and Asp95 → Gly | Φ (2), Glu91 → Gln (1) | ||
| Ser91 → Phe and Asp95 → Ala | Φ (1), Glu91 → Ala (1), Asp86 → Asn (1) | ||
| 2 | Ser91 → Phe and Asp95 → Asn | Φ (3), Glu91 → Gly (1) | 17 |
| Ser91 → Phe and Asp95 → Gly | Φ (3), Ser87 → Arg (2), Asp86 → Asn (1) | ||
| Glu91 → Gln (1) | |||
| Ser91 → Phe and Asp95 → Ala | Glu91 → Ala (2), Φ (1), Ser87 → Asn (1) | ||
| Ser91 → Phe and Ala92 → Pro | Φ (1) | ||
| Ser-91 → Phe | Glu91 → Ala (1) | ||
| 4 | Ser91 → Phe and Asp95 → Gly | Φ (8), Ser87 → Arg (5), Ser88 → Pro (1) | 28 |
| Ser91 → Phe and Asp95 → Ala | Φ (7), Glu91 → Ala (4), Asp86 → Asn (1) | ||
| Ser91 → Phe and Asp95 → Tyr | Ser87 → Arg (1) | ||
| Ser91 → Phe and Asp95 → Asn | Φ (1) | ||
| 8 | Ser91 → Phe and Asp95 → Gly | Φ (3), Ser87 → Arg (3), Asp86 → Asn (3) | 14 |
| Ser91 → Phe and Asp95 → Ala | Ser87 → Arg (2), Glu91 → Ala (1) | ||
| Ser91 → Phe and Asp95 → Asn | Asp86 → Asn (2) | ||
| 16 | Ser91 → Phe and Asp95 → Gly | Ser87 → Arg (8), Ser87 → Ile (1), Φ (1) | 13 |
| Ser91 → Phe and Asp95 → Asn | Ser87 → Ile (1), Asp86 → Asn (1), Glu91 → Gln (1) | ||
| Controls | 6 | ||
| <0.1 (GC1) | Φ | Φ | |
| <0.1 (F28) | Φ | Φ | |
| <0.1 (F45) | Φ | Φ | |
| 0.25 (GC5) | Ser91 → Tyr | Φ | |
| 8 (GC4) | Ser91 → Phe and Asp95 → Gly | Asp86 → Asn | |
| >8 (94G395) | Ser91 → Phe and Asp95 → Gly | Glu91 → Gly |
a
Φ represents QRDR without mutation. GC1, GC4, GC5, and 94G395 were QAP strains from WHO, while F28 and F45 were strains from CDC.